Comparison of the local tolerability and adhesion of a new matrix system (Menorest®) for estradiol delivery with an established transdermal membrane system (Estraderm TTS®)

Maturitas

Volumn 26, Issue 2, 1997, Pages 95-101

  Erianne, John A ^a   Winter Jr , Leo ^a  

^a Leo Winter Associates Inc   (United States)

Author keywords

adhesion; Estraderm TTS ; estradiol; matrix patch; Menorest ; reservoir patch; skin irritation; transdermal system

Indexed keywords

ESTRADIOL; PLACEBO;

ADHESION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TOLERANCE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; TRANSDERMAL DRUG ADMINISTRATION;

ABDOMEN; ADHESIVENESS; ADMINISTRATION, CUTANEOUS; ADULT; AGED; BUTTOCKS; DRUG ERUPTIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PLACEBOS; PRURITUS;

EID: 0031104728     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(96)01090-0     Document Type: Article

References (11)

1. [1] Balfour JA, Heel RC. Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990; 40: 561-582.
2. [2] Balfour JA, McTavish D. Transdermal estradiol. A review of its pharmacological profile and therapeutic potential in the prevention of postmenopausal osteoporosis. Drugs Aging 1992; 2: 487-507.
3. [3] Selby PL, Peacock M. Dose dependent response of symptoms, pituitary and bone to transdermal oestrogen in post-menopausal women. Br Med J 1986; 293: 1337-1339.
4. [4] Castelo-Branco C, Casals E, Sanllehy C, Gonzalez-Merlo J, Iglesias X. Effects of oophorectomy and hormone replacement therapy on plasma lipids. Maturitas 1993; 17: 113-122.
5. [5] Adami S, Rossini M, Zamberlan N, Bertoldo F, Dorizzi R, Lo Cascia V. Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas 1993; 17: 191-196.
6. [6] Studd JWW, McCarthy K, Zamblera D, Burger HG, Silberberg S, Wren B, Dain MP, Le Lann L, Vandepol C. Efficacy and tolerability of Menorest® compared to Premarin® in the treatment of postmenopausal women. A randomized, multicentre, double-blind, double-dummy study. Maturitas 1995; 22: 105-114.
7. [7] Gordon SF. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy. Am J Obstet Gynecol 1995; 173: 998-1004.
8. [8] Howie H, Heimer G. A multicenter randomized parallel group study comparing a new estradiol matrix patch and a registered reservoir patch. J North Am Men Soc 1995; 2: 43-48.
9. [9] Merz PG, Keller-Stanislawsky B. Bioäquivalenz von zwei Estradiol-pflastern. In: Rietbrock N, Keller-Stanislawsky B, Woodcock BG, eds. Die Haut als Transportorgan für Arzneistoffe. Darmstadt: Steinkopff Verlag, 1990.
10. [10] McCarthy T, Dramusic V, Ratnam S. Use of two types of estradiol-releasing skin patches for menopausal subjects in a tropical climate. Am J Obstet Gynecol 1992; 166: 2005-2010.
11. [11] Ducros B, Bonnin JP, Navarranne A, Colomb D. Eczema de contact à l'éthanol contenu dans une pastille d'estradiol transdermique (Estraderm TTS 50). Nouv Dermatol 1989; 8: 21-22.